(RGEN) Repligen - Ratings and Ratios
Protein A Ligands, Chromatography Columns, Filtration Systems, Process Analytics
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 47.6% |
| Value at Risk 5%th | 70.0% |
| Relative Tail Risk | -10.55% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.37 |
| Alpha | -8.55 |
| CAGR/Max DD | 0.01 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.483 |
| Beta | 1.440 |
| Beta Downside | 1.401 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.75% |
| Mean DD | 24.00% |
| Median DD | 24.07% |
Description: RGEN Repligen November 04, 2025
Repligen Corporation (NASDAQ:RGEN) is a life-sciences firm that designs, manufactures, and sells bioprocessing technologies and systems across North America, Europe, and the Asia-Pacific. Its product portfolio includes Protein A affinity ligands, cell-culture growth factors, OPUS pre-packed and small-scale chromatography columns, filtration devices such as XCell ATF and TangenX cassettes, and process-analytics tools under the SoloVPE/FlowVPE brands. Customers span biopharma, diagnostics, academic labs, and contract manufacturing organizations, and the company maintains a partnership with Navigo Proteins GmbH to co-develop new affinity ligands.
Key recent metrics: FY 2023 revenue reached approximately $1.0 billion, with a gross margin near 70% and recurring consumable sales accounting for roughly 55% of total revenue-a sign of stable, repeatable demand. The bioprocessing market is being driven by a surge in biologics pipelines (projected CAGR ≈ 10% through 2028) and the shift toward single-use, high-throughput platforms that favor Repligen’s chromatography and filtration solutions. Additionally, the company’s cash conversion cycle has shortened to under 45 days, reflecting efficient working-capital management.
For a deeper quantitative dive, the ValueRay platform offers a granular breakdown of RGEN’s financial and operational metrics.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (1.74m TTM) > 0 and > 6% of Revenue (6% = 42.5m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -0.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 136.4% (prev 165.6%; Δ -29.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 130.9m > Net Income 1.74m (YES >=105%, WARN >=100%) |
| Net Debt (-59.9m) to EBITDA (133.8m) ratio: -0.45 <= 3.0 (WARN <= 3.5) |
| Current Ratio 8.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (56.5m) change vs 12m ago -0.74% (target <= -2.0% for YES) |
| Gross Margin 45.38% (prev 47.04%; Δ -1.66pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 24.60% (prev 21.83%; Δ 2.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.59 (EBITDA TTM 133.8m / Interest Expense TTM 44.3m) >= 6 (WARN >= 3) |
Altman Z'' 3.27
| (A) 0.33 = (Total Current Assets 1.10b - Total Current Liabilities 131.1m) / Total Assets 2.92b |
| (B) 0.15 = Retained Earnings (Balance) 443.0m / Total Assets 2.92b |
| (C) 0.01 = EBIT TTM 26.1m / Avg Total Assets 2.88b |
| (D) 0.52 = Book Value of Equity 439.4m / Total Liabilities 840.6m |
| Total Rating: 3.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 37.71
| 1. Piotroski 2.50pt |
| 2. FCF Yield 1.14% |
| 3. FCF Margin 15.04% |
| 4. Debt/Equity 0.33 |
| 5. Debt/Ebitda -0.45 |
| 6. ROIC - WACC (= -9.89)% |
| 7. RoE 0.09% |
| 8. Rev. Trend -40.77% |
| 9. EPS Trend -72.98% |
What is the price of RGEN shares?
Over the past week, the price has changed by -3.53%, over one month by +13.12%, over three months by +32.45% and over the past year by +15.97%.
Is RGEN a buy, sell or hold?
- Strong Buy: 10
- Buy: 4
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RGEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 187.6 | 13.7% |
| Analysts Target Price | 187.6 | 13.7% |
| ValueRay Target Price | 180 | 9.1% |
RGEN Fundamental Data Overview December 03, 2025
P/E Trailing = 8317.501
P/E Forward = 91.7431
P/S = 13.228
P/B = 4.6214
P/EG = 2.59
Beta = 1.128
Revenue TTM = 707.9m USD
EBIT TTM = 26.1m USD
EBITDA TTM = 133.8m USD
Long Term Debt = 537.9m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 688.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -59.9m USD (from netDebt column, last quarter)
Enterprise Value = 9.30b USD (9.36b + Debt 688.9m - CCE 748.7m)
Interest Coverage Ratio = 0.59 (Ebit TTM 26.1m / Interest Expense TTM 44.3m)
FCF Yield = 1.14% (FCF TTM 106.5m / Enterprise Value 9.30b)
FCF Margin = 15.04% (FCF TTM 106.5m / Revenue TTM 707.9m)
Net Margin = 0.25% (Net Income TTM 1.74m / Revenue TTM 707.9m)
Gross Margin = 45.38% ((Revenue TTM 707.9m - Cost of Revenue TTM 386.6m) / Revenue TTM)
Gross Margin QoQ = 53.24% (prev 49.98%)
Tobins Q-Ratio = 3.18 (Enterprise Value 9.30b / Total Assets 2.92b)
Interest Expense / Debt = 3.98% (Interest Expense 27.4m / Debt 688.9m)
Taxrate = 12.86% (2.20m / 17.1m)
NOPAT = 22.8m (EBIT 26.1m * (1 - 12.86%))
Current Ratio = 8.36 (Total Current Assets 1.10b / Total Current Liabilities 131.1m)
Debt / Equity = 0.33 (Debt 688.9m / totalStockholderEquity, last quarter 2.08b)
Debt / EBITDA = -0.45 (Net Debt -59.9m / EBITDA 133.8m)
Debt / FCF = -0.56 (Net Debt -59.9m / FCF TTM 106.5m)
Total Stockholder Equity = 2.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.06% (Net Income 1.74m / Total Assets 2.92b)
RoE = 0.09% (Net Income TTM 1.74m / Total Stockholder Equity 2.03b)
RoCE = 1.02% (EBIT 26.1m / Capital Employed (Equity 2.03b + L.T.Debt 537.9m))
RoIC = 0.89% (NOPAT 22.8m / Invested Capital 2.56b)
WACC = 10.78% (E(9.36b)/V(10.05b) * Re(11.32%) + D(688.9m)/V(10.05b) * Rd(3.98%) * (1-Tc(0.13)))
Discount Rate = 11.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF Debug] Terminal Value 71.53% ; FCFE base≈116.4m ; Y1≈143.6m ; Y5≈245.0m
Fair Price DCF = 44.06 (DCF Value 2.48b / Shares Outstanding 56.3m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -72.98 | EPS CAGR: -14.01% | SUE: 0.37 | # QB: 0
Revenue Correlation: -40.77 | Revenue CAGR: 0.33% | SUE: 2.60 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.45 | Chg30d=-0.030 | Revisions Net=-6 | Analysts=15
EPS next Year (2026-12-31): EPS=2.09 | Chg30d=-0.004 | Revisions Net=-10 | Growth EPS=+25.3% | Growth Revenue=+12.6%
Additional Sources for RGEN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle